Timing of Cefuroxime Surgical Antimicrobial Prophylaxis and Its Association With Surgical Site Infections.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 Jun 2023
Historique:
medline: 12 6 2023
pubmed: 8 6 2023
entrez: 8 6 2023
Statut: epublish

Résumé

World Health Organization guidelines recommend administering surgical antimicrobial prophylaxis (SAP), including cefuroxime, within 120 minutes prior to incision. However, data from clinical settings supporting this long interval is limited. To assess whether earlier vs later timing of administration of cefuroxime SAP is associated with the occurrence of surgical site infections (SSI). This cohort study included adult patients who underwent 1 of 11 major surgical procedures with cefuroxime SAP, documented by the Swissnoso SSI surveillance system between January 2009 and December 2020 at 158 Swiss hospitals. Data were analyzed from January 2021 to April 2023. Timing of cefuroxime SAP administration before incision was divided into 3 groups: 61 to 120 minutes before incision, 31 to 60 minutes before incision, and 0 to 30 minutes before incision. In addition, a subgroup analysis was performed with time windows of 30 to 55 minutes and 10 to 25 minutes as a surrogate marker for administration in the preoperating room vs in the operating room, respectively. The timing of SAP administration was defined as the start of the infusion obtained from the anesthesia protocol. Occurrence of SSI according to Centers for Disease Control and Prevention definitions. Mixed-effects logistic regression models adjusted for institutional, patient, and perioperative variables were applied. Of 538 967 surveilled patients, 222 439 (104 047 men [46.8%]; median [IQR] age, 65.7 [53.9-74.2] years), fulfilled inclusion criteria. SSI was identified in 5355 patients (2.4%). Cefuroxime SAP was administered 61 to 120 minutes prior to incision in 27 207 patients (12.2%), 31 to 60 minutes prior to incision in 118 004 patients (53.1%), and 0 to 30 minutes prior to incision in 77 228 patients (34.7%). SAP administration at 0 to 30 minutes was significantly associated with a lower SSI rate (adjusted odds ratio [aOR], 0.85; 95% CI, 0.78-0.93; P < .001), as was SAP administration 31 to 60 minutes prior to incision (aOR, 0.91; 95% CI, 0.84-0.98; P = .01) compared with administration 61 to 120 minutes prior to incision. Administration 10 to 25 minutes prior to incision in 45 448 patients (20.4%) was significantly associated with a lower SSI rate (aOR, 0.89; 95% CI, 0.82-0.97; P = .009) vs administration within 30 to 55 minutes prior to incision in 117 348 patients (52.8%). In this cohort study, administration of cefuroxime SAP closer to the incision time was associated with significantly lower odds of SSI, suggesting that cefuroxime SAP should be administrated within 60 minutes prior to incision, and ideally within 10 to 25 minutes.

Identifiants

pubmed: 37289455
pii: 2805783
doi: 10.1001/jamanetworkopen.2023.17370
pmc: PMC10251212
doi:

Substances chimiques

Cefuroxime O1R9FJ93ED
Anti-Bacterial Agents 0
Anti-Infective Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2317370

Investigateurs

Carlo Balmelli (C)
Delphine Berthod (D)
Niccolo Buetti (N)
Philipp Jent (P)
Jonas Marschall (J)
Hugo Sax (H)
Matthias Schlegel (M)
Alexander Schweiger (A)
Laurence Senn (L)
Sarah Tschudin Sutter (S)
Aline Wolfensberger (A)
Walter Zingg (W)

Références

JAMA Netw Open. 2021 Dec 1;4(12):e2138926
pubmed: 34910149
Lancet Infect Dis. 2016 Dec;16(12):e276-e287
pubmed: 27816413
Antimicrob Agents Chemother. 1976 May;9(5):741-7
pubmed: 949172
Lancet Infect Dis. 2016 Dec;16(12):e288-e303
pubmed: 27816414
Ann Surg. 2008 Jun;247(6):918-26
pubmed: 18520217
Clin Infect Dis. 2007 Apr 1;44(7):921-7
pubmed: 17342642
J Hosp Infect. 2019 Jul;102(3):267-276
pubmed: 30529703
N Engl J Med. 2014 Mar 27;370(13):1198-208
pubmed: 24670166
Clin Infect Dis. 1994 Mar;18(3):422-7
pubmed: 8011827
Antimicrob Resist Infect Control. 2020 Dec 22;9(1):201
pubmed: 33349269
Infect Control Hosp Epidemiol. 2017 Jun;38(6):697-704
pubmed: 28558862
Surgery. 1961 Jul;50:161-8
pubmed: 16722001
Anaesthesia. 2019 Mar;74(3):373-379
pubmed: 30648259
JAMA Surg. 2017 Aug 01;152(8):784-791
pubmed: 28467526
Surg Infect (Larchmt). 2013 Feb;14(1):73-156
pubmed: 23461695
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Am J Med. 1991 Sep 16;91(3B):152S-157S
pubmed: 1656747
Infect Control Hosp Epidemiol. 2017 Oct;38(10):1172-1181
pubmed: 28826412
Infect Control Hosp Epidemiol. 1999 Apr;20(4):250-78; quiz 279-80
pubmed: 10219875
Clin Microbiol Infect. 2022 Oct;28(10):1359-1366
pubmed: 35597508
Ann Surg. 2008 Feb;247(2):343-9
pubmed: 18216543
Antimicrob Resist Infect Control. 2018 Oct 31;7:126
pubmed: 30410747
Euro Surveill. 2018 Nov;23(46):
pubmed: 30458912
Lancet Infect Dis. 2017 Jun;17(6):605-614
pubmed: 28385346
N Engl J Med. 1992 Jan 30;326(5):281-6
pubmed: 1728731
Infect Control Hosp Epidemiol. 1999 Nov;20(11):725-30
pubmed: 10580621

Auteurs

Rami Sommerstein (R)

Swissnoso, the National Center for Infection Control, Bern, Switzerland.
Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Department of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.

Nicolas Troillet (N)

Swissnoso, the National Center for Infection Control, Bern, Switzerland.
Service of Infectious Diseases, Central Institute, Valais Hospitals, Sion, Switzerland.

Stephan Harbarth (S)

Swissnoso, the National Center for Infection Control, Bern, Switzerland.
Infection Control Program, Geneva University Hospitals and Faculty of Medicine, World Health Organization Collaborating Center, Geneva, Switzerland.

Marlieke E A de Kraker (MEA)

Infection Control Program, Geneva University Hospitals and Faculty of Medicine, World Health Organization Collaborating Center, Geneva, Switzerland.

Danielle Vuichard-Gysin (D)

Swissnoso, the National Center for Infection Control, Bern, Switzerland.
Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital Thurgau, Muensterlingen and Frauenfeld, Switzerland.

Stefan P Kuster (SP)

Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St Gallen, Switzerland.

Andreas F Widmer (AF)

Swissnoso, the National Center for Infection Control, Bern, Switzerland.
Department of Infectious Diseases, University Hospital Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH